Screener
InMed Pharmaceuticals INM Q1 2026 earnings
Reported May 6, 2026 · Before market open
Revenue$1.3MMiss by $658.6M
EPS-$0.69Beat by $93.75
Revenue estimate$659.8M
EPS estimate-$94.44
Next report
Nov 5, 2026 (In 3 days)Revenue estimate$300.0K
EPS estimate-$94.44
Versus estimates
Revenue
Diluted EPS
Q2 2026-$1.43Beat by $93.01
Q1 2026-$0.69Beat by $93.75
Q4 2025-$0.51Q3 2025-$0.44Q2 2025-$3.80Q1 2025-$1.94FAQ
- When did InMed Pharmaceuticals report Q1 2026 earnings?
- InMed Pharmaceuticals (INM) reported Q1 2026 earnings on May 6, 2026 before market open.
- What were InMed Pharmaceuticals's Q1 2026 revenue and EPS?
- InMed Pharmaceuticals reported revenue of $1.3M and eps of $-0.69 for Q1 2026.
- Did InMed Pharmaceuticals beat estimates in Q1 2026?
- Revenue missed the consensus estimate of $659.8M by $658.6M. EPS beat the consensus estimate of $-94.44 by $93.75.
- How did InMed Pharmaceuticals's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue declined 29.8% from $1.8M a year earlier and eps grew 64.4% from $-1.94.
- Where can I find InMed Pharmaceuticals's Q1 2026 SEC filings?
- You can read the 8-K earnings release (0001062993-26-002371) and the 10-Q periodic report (0001213900-26-052920) directly on SEC EDGAR. The filing index links above go to sec.gov.
